Login to Your Account

Spinout Obseva Targets Preterm Labor Drug

By Marie Powers
Staff Writer

Thursday, August 29, 2013
Merck Serono SA spinout Obseva SA hit the ground running with a CHF32 million (US$34.7 million) Series A financing led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription